Content about Avastin

March 21, 2013
Ga. compounding pharmacy recalls all lots of sterile products

A compounding pharmacy in Georgia is recalling all of its sterile products following a Food and Drug Administration investigation that found possible lack of proper sanitation procedures, the FDA said.

SILVER SPRING, Md. — A compounding pharmacy in Georgia is recalling all of its sterile products following a Food and Drug Administration investigation that found possible lack of proper sanitation procedures, the FDA said Thursday.

February 8, 2013
Reports: Amgen plans six biosimilars

Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

NEW YORK — Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

February 15, 2012
Counterfeit Avastin circulating in U.S., FDA warns

Fake versions of a cancer drug made by Roche's U.S. unit have entered the United States, the Food and Drug Administration warned Wednesday.

SILVER SPRING, Md. — Fake versions of a cancer drug made by Roche's U.S. unit have entered the United States, the Food and Drug Administration warned Wednesday.

The FDA advised healthcare professionals and patients that a counterfeit version of Genentech's Avastin (bevacizumab) had been distributed in the United States. The agency said the counterfeit versions carried Roche's logo instead of Genentech's and displayed batch numbers starting with B6010, B6011 or B86017.

November 18, 2011
FDA revokes breast cancer approval for Avastin

A drug widely used to treat breast cancer is not safe or effective, the Food and Drug Administration said Friday.

SILVER SPRING, Md. — A drug widely used to treat breast cancer is not safe or effective, the Food and Drug Administration said Friday.

February 9, 2011
Genentech: Avastin boosts chances of progression-free survival among ovarian cancer patients

Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

SOUTH SAN FRANCISCO, Calif. — Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

Genentech, part of Swiss drug maker Roche, announced results from its phase-3 “OCEANS” study, in which women with recurring ovarian cancer received Avastin (bevacizumab) with gemcitabine and carboplatin, both chemotherapy drugs, followed by use of Avastin alone.

January 19, 2011
Genentech appeals FDA's plan to pull Avastin off market

Drug maker Genentech is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke its approval for the disease, according to published reports.

NEW YORK — Drug maker Genentech is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke its approval for the disease, according to published reports.

The San Francisco Business Times reported Tuesday that Genentech, part of Swiss drug maker Roche, is appealing the FDA’s plan to revoke approval for the drug Avastin (bevacizumab) as a first-line treatment for advanced HER2-negative breast cancer in combination with paclitaxel chemotherapy.

December 16, 2010
FDA looks to pull the plug on Avastin's breast cancer indication

Just a few months after a Food and Drug Administration advisory committee recommended limiting the use of a Genentech drug designed to treat breast cancer, the regulatory agency is looking to revoke the approval altogether.

SILVER SPRING, Md. — Just a few months after a Food and Drug Administration advisory committee recommended limiting the use of a Genentech drug designed to treat breast cancer, the regulatory agency is looking to revoke the approval altogether.